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Vascular Radiation Therapy:
The Devil Is in the Dose*
Paul S. Teirstein, MD, FACC
La Jolla, California
It is not unusual for a promising new technology to enjoy an
initial heady period of excitement that is tempered by the
accrual of more comprehensive data. Intravascular radiation
as a treatment for restenosis has recently enjoyed enthusi-
astic support born out of several, very promising early
reports. In the SCRIPPS trial, catheter-based gamma radi-
ation using iridium-192 reduced angiographic, ultrasono-
graphic and clinical indexes of restenosis by approximately
two thirds (1). Recently, these results were confirmed by the
WRIST trial, where patients with in-stent restenosis treated
with iridium-192 demonstrated a nearly identical reduction
in restenosis (2). In the BERT trial, beta radiation using
strontium-90/yttrium-90 was also associated with high
six-month angiographic and clinical success rates (3). The
concordance of these trial results strengthens our belief in
the power of catheter-based radiation to limit the prolifer-
ative response to injury after angioplasty. However, in the
shadow of these very positive reports lurk less compelling,
and in some recent cases, disturbing data.
In this issue of the Journal, Hehrlein et al. (4) describe one
such negative trial using external beam radiation (EBR) in
the rabbit stent injury model of restenosis. If EBR were a
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safe and effective method of treating restenosis, it would
have many advantages over catheter-based techniques. Ex-
ternal beam radiation is more practical to administer be-
cause it is delivered in the radiotherapy suite, far from the
catheterization laboratory, without the need for indwelling
catheters. External beam radiation does not prolong the
catheterization procedure by the 10 to 30 min required for
catheter-based radiotherapy. Also, EBR need not be admin-
istered at the time of angioplasty, but can be delivered in
several fractions, or delayed by one or more days as proven
desirable in at least one animal study (5).
It is disappointing, therefore, that in the rabbit stent
model, Hehrlein and his colleagues were unable to demon-
strate benefit, and in fact report an acceleration of neointi-
mal proliferation in response to EBR. Their report is the
third animal trial to associate EBR with increased restenosis
after angioplasty (6,7). All three trials used different EBR
dose regimens and different animal models, yet all reported
remarkably similar results. External beam radiation deliv-
ered at doses of 4 to 16 Gy increased rather than decreased
neointimal proliferation. Hehrlein et al. further analyzed
this phenomenon using immunohistochemistry and North-
ern blot analysis to localize the cause of neointimal growth
to both extracellular matrix formation and increased smooth
muscle cell division. One ominous finding was an increased
rate of smooth muscle cell proliferation in vascular regions
within the radiated field but outside the stented (i.e.,
injured) vessel segment. This highlights the potential dan-
ger of radiation causing accelerated vascular pathology in
previously nondiseased vessel segments. This iatrogenic
problem has similarities to that recently encountered in an
early clinical dose-finding study at the margins of
phosphorous-32 (P-32) radioactive stents (see following
discussion).
Why might EBR fail despite so many successful animal
and clinical trials using catheter-based techniques? Why
would delivery of radiation by one method suppress, yet by
another, stimulate restenosis? The devil likely lies in the
dose delivered. When radiation is delivered by a catheter (or
stent), a dose gradient is created between the source (located
within the vessel lumen) and the target (the vessel wall).
Higher doses are delivered to the intima, whereas lower
doses are delivered to the media and even lower doses to the
adventitia. In contradistinction, when radiation is delivered
by EBR, a large volume of tissue surrounding the vessel is
exposed to a homogeneous dose of radiation. Radiation may
suppress proliferation when delivered as a dose gradient
across the vessel wall by catheters, yet stimulate proliferation
when delivered as one dose (particularly if it is the wrong
dose) to the entire thickness of the wall by EBR. For
example, in the SCRIPPS trial (8), successful inhibition of
restenosis was observed when 20 to 30 Gy was delivered to
the adventitial border closest to the radiation source and 8
Gy was delivered to the adventitial border furthest from the
source. A dose of 30 Gy delivered to the adventitial border
closest to the source results in 40 to 50 Gy delivered to the
region of the luminal surface making direct contact with the
delivery catheter. Thus a dose gradient from approximately
50 to 8 Gy was created across the vessel wall. In the
disappointing EBR studies, perhaps the dose to the inner
layers of the vessel wall (i.e., intima–media) was too low or,
alternatively, the dose to the outer layers of the wall (i.e.,
media–adventitia) may have been too high. It is conceivable,
therefore, that EBR would be successful if a different dose
were used. This is supported by a recent report where EBR
at 21 Gy but not 14 Gy was associated with reduced
restenosis in the pig overstretch angioplasty model (9).
However, in that trial, 21 Gy was also associated with
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myocardial edema, necrosis and fibrosis. Therefore EBR at
doses lower than 16 Gy appears to be ineffective or to
increase restenosis, whereas doses higher than 16 Gy expose
large volumes of cardiac tissue to radiation levels that could
have deleterious long-term effects.
The present negative report comes at a time when several
other trials have raised doubts regarding vascular applica-
tions of radiotherapy. Recently, a clinical trial using P-32
beta–emitting radioactive stents has reached a significant
roadblock (10). Early reports indicate that low activity P-32
stents (0.75 to 3.0 mCi) have no impact on restenosis,
whereas intermediate activity stents (3 to 12 mCi) effectively
abolish neointimal formation within the stented segment,
but promote neointimal proliferation and unfavorable re-
modeling at the stent margins. These iatrogenic “edge”
stenoses have been termed the “candy wrapper” effect,
because their angiographic appearance is similar to the
packaging of tubular shaped candies. This stent “edge effect”
causes a high need for repeat revascularization, which
cancels out the beneficial effects of radiation observed inside
the body of the stent. In the P-32 stented vessel, radioac-
tivity is profoundly reduced as one moves longitudinally
away from the stent struts. It is likely, therefore, that when
vessel wall components at the stent margins are exposed to
a lower dose of radiation, cell division is stimulated. This
paradoxical stimulation of neointimal formation by a lower
than therapeutic dose of radiation is a new and troubling
problem confronting the vascular radiation field.
In another trial, Condado et al. (11,12) in Venezuela (the
first investigators to use radiation in human coronary arter-
ies), found that iridium-192 administered to 21 patients in
doses as high as 92 Gy appeared to reduce restenosis, but
also resulted in four aneurysms, including one pseudoaneu-
rysm. Here the maximal dose of 92 Gy used was more than
three times the maximal dose allowed in the SCRIPPS trial.
Conversely, in the GENEVA trial (13), 15 patients were
treated with strontium-90, a beta emitter, and although no
adverse effects were reported, restenosis rates were similar to
historical control rates. Here the dose delivered was so low
(18 Gy to the vessel surface but less than 3 Gy at 2 mm into
the vessel wall) that, in essence, placebo was administered
(14).
In the Venezuelan trial, the dose was clearly too high. In
the GENEVA trial, the dose was too low. In the negative
EBR trials, the dose used was probably too low, yet the
volume of tissue irradiated was too large to safely allow
higher dose exposures. In the radioactive stent trial, the dose
inside the stent appeared adequate, but at the stent margins,
where the dose falls off, new stenoses were created. These
results underscore the complex nature of the biologic tissue
response to radiation. Clearly, proper dosimetry is essential.
Cardiologists are now learning the biologic importance of
basic radiation physics such as depth dose, dose gradient,
dose rate and dose volume (15).
Finding the proper dose for each of the numerous
vascular radiation therapies currently under investigation
remains a significant challenge. Each radiotherapy isotope
and delivery system will likely require its own dosimetry
trial, where different doses and different delivery techniques
are tested. Some, like EBR, are likely to fail. Others, like the
P-32 beta–emitting stent, may require alterations in design.
The current radioactive stent feasibility trial is testing stents
at higher activities (up to 20 mCi). If stimulation of
neointimal proliferation is still observed at the margins of
these higher activity stents, more dramatic changes may be
required. For example, perhaps loading the stent edges with
higher activity P-32 relative to the stent body will overcome
the proliferative effect. Alternatively, the P-32 stent’s Achil-
les’ heel may be its extremely low dose rate. This stent is a
permanent implant resulting in the continuous emission of
radiation over about 5 half-lives (14.3 days). Thus, the
arterial wall is bombarded with electrons for more than 2
months. Success may require selection of a different isotope
with a shorter half-life, thus increasing the dose rate and
making the exposure time more like that of the more
successful catheter-based techniques.
Of course, the major concern raised by the work of
Hehrlein et al.(4), and other EBR animal studies, is the
possibility of late complications caused by vascular radiation
exposure. Long-term adverse events after radiation therapy
using EBR for nonvascular indications are well docu-
mented. Potential complications include accelerated vascu-
lar disease, coronary perforation and late malignancy. Ac-
celerated vascular disease has been reported in patients
irradiated using EBR for treatment of Hodgkin disease
followed beyond seven to nine years (16). It is important to
emphasize the differences between catheter-based vascular
radiation and EBR. In catheter-based intravascular brachy-
therapy, the volume of irradiation is small, with significant
radial dose falloff from the lumen to the adventitia. Addi-
tionally, only a single vessel is radiated over a limited
longitudinal segment with little exposure to the surrounding
normal tissue. This results in a relatively small volume of
vascular tissue irradiated. Thus, the risk of radiation-
induced fibrosis or atherosclerosis is believed to be much
lower than that which occurs from the treatment of
Hodgkin disease, where a much larger volume of tissue is
irradiated.
High doses of radiation could also lead to vascular rupture
(17,18). Perforation and/or pseudoaneurysm of coronary
arteries would likely be detected in the first few months after
treatment. In most vascular radiation trials, the careful
avoidance of .50 to 60 cGy to any one part of the luminal
surface, with much lower doses delivered to the adventitial
layers, probably reduces the risk of vessel perforation. To
date, with the exception of the data from Venezuela, there
have been no reports of aneurysm or pseudoaneurysm
formation in the nearly 1,000 patients treated with vascular
radiation in other clinical trials.
Secondary malignancies after radiation range from leuke-
mia to solid tumors. Hematologic malignancies and solid
tumors are usually seen within the first 3 to 10 years in
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cancer patients who receive combination chemotherapy,
who are often immunocompromised (19,20). Again, it must
be emphasized that the volume of radiation in intravascular
brachytherapy is extremely small, making secondary malig-
nancy unlikely. Indeed, a patient’s total body exposure from
a catheter-based gamma radiation vascular procedure is
estimated to be approximately 10 mSv, which is similar to
the exposure from a typical 3-mCi thallium-201 stress test
(6.3 mSv), and lower than the usual exposure from diag-
nostic coronary angiography (up to 15 mSv) (Wim Dries,
personal communication). Also, decades of experience using
radiation therapy in other benign proliferative disorders
(i.e., heterotopic ossification and keloid scars) have docu-
mented the procedure’s long-term safety. Finally, bear in
mind that for the patient with recurrent restenosis, the
theoretical possibility of a late adverse event due to radiation
is often far less compelling than the very real and debilitat-
ing cardiac problem radiation therapy is being called upon
to solve.
Radiation therapy has now been used to treat benign and
malignant disorders for over 100 years. The early and
intermediate (up to three-year follow-up) results using
iridium-192 and strontium-90/yttrium-90 to treat vascular
restenosis remain very encouraging, particularly at the dose
range used in the SCRIPPS, WRIST and BERT trials.
However, as more data accumulate, the effects of vascular
radiation are proving increasingly complex. Cardiologists,
collaborating with their colleagues in the radiotherapy
department, have learned that to optimize safety and effi-
cacy, meticulous attention to dosimetry must be an obses-
sion for oncologists and physicists. Despite encouraging
news from most of the early clinical vascular radiation trials,
problems encountered in some recent trials should be
sobering. These negative trials teach us that although
radiation may be the answer to restenosis, the devil lies in
the details, and in radiation the most important detail is the
dose.
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